| Budget Amount *help |
¥17,030,000 (Direct Cost: ¥13,100,000、Indirect Cost: ¥3,930,000)
Fiscal Year 2013: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2012: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2011: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
|
|---|
| Research Abstract |
The aim of this study was to evaluate the feasibility of percutaneous isolated pancreas perfusion (PIPP). (1) Animal study: PIPP was performed at 4 infusion rates. The organs were examined angiographically and histopathologically, and the maximum platinum concentration (Cmax) and the concentration–time curve (AUC) were measured. (2) Clinical study: We have begun the 3 + 3 cisplatin (from 20 mg/m2) dose-escalation design was selected to determine the dose-limiting adverse events toxicity (DLT) and maximum tolerated dose for advanced pancreas cancer. (1) Angiography confirmed the PIPP system. Histopathological examinations showed no abnormalities in the pancreas only at an infusion rate of 40 ml/min. The pancreas to systemic exposure ratio was over 70-fold in terms of Cmax and 58-fold in terms of AUC. (2) PIPP was successfully performed in 5 patients. No DLTs were observed until 25 mg/m2 of cisplatin. In conclusion, PIPP appears a safe and feasible technique for pancreas cancer.
|
